Cooperative Ovarian Cancer Group for Immunotherapy Network Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2013
NCT01847274
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

COGI: Cooperative Ovarian Cancer Group for Immunotherapy | Cooperative Ovarian Cancer Group for Immunotherapy (COGI) Network

Active Ingredients

Drugs in Phase 3 Trials (1)

niraparib (zejula) (1 trial)

Drugs in Phase 2 Trials (4)

durvalumab (imfinzi) (1 trial)

medi0562 (1 trial)

oleclumab (1 trial)

tremelimumab (Imjudo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Ovarian Epithelial (Phase 3)

Hypersensitivity (Phase 3)

Ovarian Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 5